Literature DB >> 192830

Plasma levels of a viral protein as a diagnostic signal for the presence of mammary tumor: the effect of tumor removal.

E Ritzi, D S Martin, R L Stolfi, S Spiegelman.   

Abstract

We have previously shown (1, 2) that mice with mammary tumors can always be identified by their very high plasma levels of gp52, a 52,000 mol wt glycoprotein of the mouse mammary tumor virus (MMTV). The present investigation demostrates that the tumor is the principal source of the plasma gp52 since surgical excision is invariably followed in the first 9 days by a sharp decreasing (10-100-fold) of the gp52 levels. Control animals in which the tumors were left in place by a "sham" surgical procedure maintained their high level of gp52, which continued to increase as the disease progressed. The behavior of the gp52 after surgical removal suggests that gp52 plasma concentrations are diagnostically and prognostically informative, as indicated by the following finding: (a) All tumor recurrences were correctly diagnosed by increases in gp52 levels, and some were detected 4-7 days before they were found by palpation. (b) Tumor regrowths were accompanied by continued increases in plasma gp52 concentrations at rates that usually matched the speed of tumor development. (c) The only animals that remained tumor free at the termination of the experiment were those that maintained their gp52 levels at or below 15 ng/ml. (d) The probability of a tumor-free animal relapsing within 2 wk is much higher if its gp52 level is above the mean. (e) More remarkably, the plasma levels of gp52 at the time of surgery are superior to the size of the tumors removed as prognostic indicators of eventual surgical "cures". The availability of a specific and sensitive systemic measure of disease status should augment the usefulness of the murine mammary tumor model by catalyzing a more rapid acquisition of information on the therapeutic effectiveness of the new and varied drug combinations being tested for adjuvant chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 192830      PMCID: PMC2180620          DOI: 10.1084/jem.145.4.999

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  7 in total

1.  The purification of a gs antigen of the murine mammary tumor virus and its quantitation by radioimmunoassay.

Authors:  E Ritzi; A Baldi; S Spiegelman
Journal:  Virology       Date:  1976-11       Impact factor: 3.616

2.  Homology between human breast tumour RNA and mouse mammary tumour virus genome.

Authors:  A B Vaidya; M M Black; A S Dion; D H Moore
Journal:  Nature       Date:  1974-06-07       Impact factor: 49.962

3.  Virus-related RNA in human and mouse mammary tumors.

Authors:  S Spiegelman; R Axel; J Schlom
Journal:  J Natl Cancer Inst       Date:  1972-04       Impact factor: 13.506

4.  Immunology of spontaneous mammary carcinomas in mice. V. Acquired tumor resistance and enhancement in strain A mice infected with mammary tumor virus.

Authors:  M A Attia; D W Weiss
Journal:  Cancer Res       Date:  1966-08       Impact factor: 12.701

5.  Particles containing RNA-instructed DNA polymerase and virus-related RNA in human breast cancers.

Authors:  R Axel; S C Gulati; S Spiegelman
Journal:  Proc Natl Acad Sci U S A       Date:  1972-11       Impact factor: 11.205

6.  Plasma levels of a viral protein as a diagnostic signal for the presence of tumor : the murine mammary tumor model.

Authors:  E Ritzi; D S Martin; R L Stolfi; S Spiegelman
Journal:  Proc Natl Acad Sci U S A       Date:  1976-11       Impact factor: 11.205

7.  Cellular hypersensitivity of gp55 of RIII-murine mammary tumor virus and gp55-like protein of human breast cancers.

Authors:  M M Black; R E Zachrau; A S Dion; B Shore; D L Fine; H P Leis; C J Williams
Journal:  Cancer Res       Date:  1976-11       Impact factor: 12.701

  7 in total
  8 in total

1.  Detection of viral proteins in mouse mammary tumors by immunoperoxidase staining of paraffin sections.

Authors:  I Keydar; R Mesa-Tejada; M Ramanarayanan; T Ohno; C Fenoglio; R Hu; S Spiegelman
Journal:  Proc Natl Acad Sci U S A       Date:  1978-03       Impact factor: 11.205

2.  Detection in human breast carcinomas of an antigen immunologically related to a group-specific antigen of mouse mammary tumor virus.

Authors:  R Mesa-Tejada; I Keydar; M Ramanarayanan; T Ohno; C Fenoglio; S Spiegelman
Journal:  Proc Natl Acad Sci U S A       Date:  1978-03       Impact factor: 11.205

3.  Radioimmunoassays for the 36,000-dalton glycoprotein of murine mammary tumor viruses demonstrate type, group, and interspecies determinants.

Authors:  Y A Teramoto; J Schlom
Journal:  J Virol       Date:  1979-08       Impact factor: 5.103

4.  Immunological characterization of mouse mammary tumor virus p10 and its presence in mammary tumors and sera of tumor-bearing mice.

Authors:  L O Arthur; D L Fine
Journal:  J Virol       Date:  1979-04       Impact factor: 5.103

5.  Detection and characterization of mouse mammary tumor virus cell surface antigens: estimation of antigen abundance by protein A assay.

Authors:  A H Callis; E M Ritzi
Journal:  J Virol       Date:  1980-09       Impact factor: 5.103

6.  Virolysis of mouse mammary tumor virus by sera from breast cancer patients.

Authors:  S S Witkin; R A Egeli; N H Sarkar; R A Good; N K Day
Journal:  Proc Natl Acad Sci U S A       Date:  1979-06       Impact factor: 11.205

7.  Properties of retrovirus-like particles produced by a human breast carcinoma cell line: immunological relationship with mouse mammary tumor virus proteins.

Authors:  I Keydar; T Ohno; R Nayak; R Sweet; F Simoni; F Weiss; S Karby; R Mesa-Tejada; S Spiegelman
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

8.  Improving the anti-tumor activity of 5-fluorouracil by increasing its incorporation into RNA via metabolic modulation.

Authors:  S Spiegelman; R Sawyer; R Nayak; E Ritzi; R Stolfi; D Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1980-08       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.